Heather McArthur, MD, MPH, FASCO

Listen to @hmcarthur give a brief synopsis of her 2025 IBC East presentation. Watch the full interview here: cancernetwork.com/clinical/breas…

ICYMI: @hmcarthur of @UTSWMedCenter discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative #breastcancer🌸. Watch the full video below 📺: onclive.com/view/dr-mcarth… @gotoPER #bcsm #oncology

.@hmcarthur stopped by to discuss updates in immunotherapy for patients with high-risk early-stage breast cancer. #bcsm

Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone receptor–positive/HER2-negative breast cancer. #bcsm | @hmcarthur @UTSWMedCenter hubs.li/Q03w5ck00

.@hmcarthur joins experts in an @OncLive discussion on #ASCO25 updates in HER2-positive metastatic breast cancer, covering first-line treatments, sequencing, and the role of CDK4/6 inhibitors for personalized care. bit.ly/3T25zz6

@hmcarthur and colleagues discuss the role of the CLEOPATRA regimen (docetaxel, trastuzumab, and pertuzuma as first-line treatment for HER2-positive metastatic breast cancer, Watch their full discussion here: hubs.li/Q03vnS4T0

ICYMI: @hmcarthur of @UTSWMedCenter discusses the expanding clinical role for ADCs like T-DXd in HER2-positive breast cancer. Watch the full clip below 📺: onclive.com/view/dr-mcarth… @ASCO #ASCO25 #bcsm #oncology

As a panelist in @CancerNetwrk's latest discussion, @hmcarthur, Clinical Director of our Breast Cancer Program, shares expert insights on evolving personalized approaches for treating HER2-positive breast cancer. bit.ly/4ncQWGS

During a live event, Heather L. McArthur, MD, MPH, reviewed genomic assays for early-stage breast cancer. #bcsm | @hmcarthur @UTSWMedCenter hubs.li/Q03t5qWV0

Starting June 9th at 5 PM EDT/4 PM CDT, catch @VKaklamani and @hmcarthur discussing key breast cancer trials following #ASCO25. #bcsm

ASCO dropped the data, now our experts help you take it from podium to practice. Watch now for concise recaps of top trials from #ASCO25. 📈 Top takeaways 🩺Real-world application 🇨🇦 Multiple tumour sites, CDN perspective. 📹 ow.ly/xCwZ50W5LKI @GillSharlene @Nimira_A

🚨 If you're as serious about breast cancer care as @DrReshmaMahtani, @baik_alan, @antgiorda, @DrSGraff, @claudine_isaacs, @FilipaLynce, @hmcarthur, @DrKEMcCann, @folopade, @kristinrojasmd, @drsarahsam, @Dr_RShatsky, @BCJoyceO then you won't miss #PBCCLive25 in DC! It's the…

So proud of you @AlexisLevee! @hmcarthur #ASCO25

My poster neighbors— “The study was negative, but the friendship was positive” @hmcarthur @MIgnatiadis #ASCO25

Love that @ConquerCancerFd managed to capture in the video below this simply magical moment when @AlexisLevee won her @ASCO YIA! It has been a joy to co-mentor this superstar in #breastcancer w @hmcarthur @utswcancer (Heather, TY! As a #kidneycancer doc I was way out of my…

Hear @ErikaHamilton9 of @SarahCannonDocs, @hmcarthur of @UTSWMedCenter, and @DrKEMcCann of @UCLA discuss sequencing for HER2+ metastatic breast cancer after progression on first-line therapy.. Watch more here: hubs.li/Q03n-vRJ0

What is the cause of ADC-related ILD? Spoiler: most likely not the antibody target (e.g. not HER2). New data confirms prior observations that T-DXd affects alveolar macrophages (AM) via Fc–FcγR engagement, triggering immune activation and ultimately ILD. aacrjournals.org/cancerres/arti…

Discussing adjuvant therapy as well as post mastectomy radiation. And who better to talk about all this than this panel @stolaney1 @hmcarthur @_MDEducation

TDXd + pertuzumab improves PFS in 1st line DB-09! #HER2 #bcsm @OncoAlert @OncBrothers astrazeneca.com/media-centre/p…

Congratulations @AlexisLevee! Such a pleasure to collaborate with you!! Looking forward to celebrating your many future successes!!